IL28696A - Attenuated live rubella virus vaccine and method of production - Google Patents
Attenuated live rubella virus vaccine and method of productionInfo
- Publication number
- IL28696A IL28696A IL28696A IL2869667A IL28696A IL 28696 A IL28696 A IL 28696A IL 28696 A IL28696 A IL 28696A IL 2869667 A IL2869667 A IL 2869667A IL 28696 A IL28696 A IL 28696A
- Authority
- IL
- Israel
- Prior art keywords
- rubella
- vaccine
- rubella virus
- virus
- attenuated live
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 30
- 230000002238 attenuated effect Effects 0.000 title claims description 11
- 229940124968 Rubella virus vaccine Drugs 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title description 2
- 241000710799 Rubella virus Species 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 15
- 201000005404 rubella Diseases 0.000 claims description 10
- 210000005084 renal tissue Anatomy 0.000 claims description 6
- 230000001018 virulence Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229960003131 rubella vaccine Drugs 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 19
- 241000700605 Viruses Species 0.000 description 14
- 239000012530 fluid Substances 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 8
- 241000282693 Cercopithecidae Species 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 230000000405 serological effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000009781 safety test method Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 231100000041 toxicology testing Toxicity 0.000 description 4
- 108010079058 casein hydrolysate Proteins 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241000709700 Coxsackievirus A9 Species 0.000 description 2
- 241000709714 Echovirus E11 Species 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000013919 monopotassium glutamate Nutrition 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000700198 Cavia Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/20—Rubella virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36211—Rubivirus, e.g. rubella virus
- C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB47399/66A GB1135987A (en) | 1966-10-21 | 1966-10-21 | Attenuated live rubella virus vaccine and method of production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL28696A true IL28696A (en) | 1971-12-29 |
Family
ID=10444820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL28696A IL28696A (en) | 1966-10-21 | 1967-09-29 | Attenuated live rubella virus vaccine and method of production |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US3686394A (de) |
| AT (1) | AT279038B (de) |
| BE (1) | BE705342A (de) |
| BR (1) | BR6794003D0 (de) |
| CA (1) | CA956232A (de) |
| CH (1) | CH477553A (de) |
| CY (1) | CY635A (de) |
| DE (1) | DE1617775B1 (de) |
| DK (1) | DK121619B (de) |
| ES (1) | ES345972A1 (de) |
| FI (1) | FI43625B (de) |
| FR (2) | FR7321M (de) |
| GB (1) | GB1135987A (de) |
| IL (1) | IL28696A (de) |
| LU (1) | LU54664A1 (de) |
| NL (1) | NL148799B (de) |
| NO (1) | NO125776B (de) |
| SE (1) | SE341451B (de) |
| YU (1) | YU31804B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2129777C3 (de) * | 1971-06-16 | 1982-04-15 | Takeda Chemical Industries, Ltd., Osaka | Verfahren zur Herstellung eines stark ageschwächte Rötelviren enthaltenden Impfstoffes |
| FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| RU2213776C2 (ru) * | 2001-11-20 | 2003-10-10 | Унитарное государственное московское предприятие по производству бактерийных препаратов Минздрава РФ | Способ получения адаптированного к фибробластам эмбрионов перепела вируса краснухи |
| US8460680B2 (en) * | 2009-04-24 | 2013-06-11 | National Health Research Institutes | Polyvalent chimeric rubella virus-based vaccines |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3401084A (en) * | 1965-07-29 | 1968-09-10 | Merck & Co Inc | Rubella vaccine and its preparation |
-
1966
- 1966-10-21 GB GB47399/66A patent/GB1135987A/en not_active Expired
-
1967
- 1967-09-29 IL IL28696A patent/IL28696A/en unknown
- 1967-10-05 CA CA001,858A patent/CA956232A/en not_active Expired
- 1967-10-11 US US674650A patent/US3686394A/en not_active Expired - Lifetime
- 1967-10-11 ES ES345972A patent/ES345972A1/es not_active Expired
- 1967-10-12 LU LU54664D patent/LU54664A1/xx unknown
- 1967-10-13 CH CH1432067A patent/CH477553A/fr not_active IP Right Cessation
- 1967-10-17 FI FI2788/67A patent/FI43625B/fi active
- 1967-10-18 FR FR124840A patent/FR7321M/fr not_active Expired
- 1967-10-18 BR BR194003/67A patent/BR6794003D0/pt unknown
- 1967-10-18 FR FR1548489D patent/FR1548489A/fr not_active Expired
- 1967-10-18 YU YU2034/67A patent/YU31804B/xx unknown
- 1967-10-19 NO NO170199A patent/NO125776B/no unknown
- 1967-10-19 DE DE1967R0047176 patent/DE1617775B1/de active Pending
- 1967-10-19 NL NL676714223A patent/NL148799B/xx not_active IP Right Cessation
- 1967-10-19 AT AT946167A patent/AT279038B/de not_active IP Right Cessation
- 1967-10-19 BE BE705342D patent/BE705342A/xx not_active IP Right Cessation
- 1967-10-20 SE SE14398/67A patent/SE341451B/xx unknown
- 1967-10-20 DK DK525067AA patent/DK121619B/da not_active IP Right Cessation
-
1972
- 1972-03-07 CY CY63572A patent/CY635A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CH477553A (fr) | 1969-08-31 |
| NO125776B (de) | 1972-10-30 |
| US3686394A (en) | 1972-08-22 |
| CA956232A (en) | 1974-10-15 |
| GB1135987A (en) | 1968-12-11 |
| LU54664A1 (de) | 1967-12-12 |
| FR7321M (de) | 1969-10-06 |
| SE341451B (de) | 1971-12-27 |
| YU203467A (en) | 1973-06-30 |
| BE705342A (de) | 1968-03-01 |
| FR1548489A (de) | 1968-12-06 |
| AT279038B (de) | 1970-02-25 |
| CY635A (en) | 1972-03-07 |
| YU31804B (en) | 1973-12-31 |
| BR6794003D0 (pt) | 1973-02-22 |
| ES345972A1 (es) | 1968-12-01 |
| NL148799B (nl) | 1976-03-15 |
| NL6714223A (de) | 1968-04-22 |
| DE1617775B1 (de) | 1970-10-22 |
| DK121619B (da) | 1971-11-08 |
| FI43625B (de) | 1971-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Elek et al. | Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero | |
| Caunt et al. | Neutralization tests with varicella-zoster virus | |
| US3959466A (en) | Highly attenuated cytomegalovirus vaccine and production thereof | |
| US4000256A (en) | Varicella vaccine and process for its preparation | |
| Beare et al. | Investigation into the attenuation of influenza viruses by serial passage | |
| US3501770A (en) | Shipping fever vaccine | |
| US3927208A (en) | Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them | |
| ANDERSEN | Complement‐fixing and virus‐neutralizing antibodies in cytomegalovirus infection as measured against homologous and heterologous antigen | |
| US3354038A (en) | Serial passaging tissue cultured canine distemper virus to form attenuated vaccine short of virus-antigenicity decreasing passages | |
| US3907986A (en) | Live attenuated infectious bovine rhinotracheitis virus vaccines and preparation thereof | |
| Plotkin et al. | Intranasally administered rubella vaccine | |
| Grayston | Immunization against trachoma | |
| US3686394A (en) | Attenuated live rubella virus vaccine and method of production | |
| White et al. | Prevalence of antibody to poliovirus in England and Wales 1984-6. | |
| US3925544A (en) | Bovine vaccines and methods of making and using same | |
| NO170199B (no) | Fremgangsmaate for loesbar fastgjoering av et siktelement i en holder i et vibrasjonssikteapparat, og vibrasjons-sikteapparat som et slikt siktelement kan monteres i | |
| US3897549A (en) | Herpes simplex type 2 virus vaccine and method of production and use | |
| Ueda et al. | Immunological relationship between herpes simplex virus and B virus | |
| Smith | A localized outbreak of dengue fever in Kuala Lumpur: serological aspects | |
| Auletta et al. | An improved diluent for rubella hemagglutination and hemagglutination-inhibition tests | |
| Field | The occurrence of neutralizing and complement fixing antibodies in rubella | |
| US3366543A (en) | Process of attenuating infectious bovine rhinotracheitis viruses | |
| US3098011A (en) | Process of producing a vaccine against distemper | |
| Goldblum et al. | Immunization with live attenuated rubella virus vaccine (HPV-77): Clinical and serological results in children and adolescents in Israel | |
| US3544680A (en) | Intranasal immunization against rubella |